6 research outputs found
Performances of DILI-ActiTest, apoA1 and haptoglobin, for the prediction of recovery.
<p>DILI-ActiTest ‘s AUROC = 0.723 (95%CI 0.610–0.806 P<0.001 vs. 0.5). The AUROCs of APOA1, and HAPTO were 0.663 (0.536–0.76; P = 0.004 vs 0.5; P = 0.14 vs DILI-ActiTest), and 0.619 (0.496–0.718; P = 0.04 vs 0.500; p = 0.05 vs DILI-ActiTest).</p
Characteristics of patients adjudicated as DILI or not, among the population suspected cases, the context of use population (n = 176).
<p>Characteristics of patients adjudicated as DILI or not, among the population suspected cases, the context of use population (n = 176).</p
Summary of significant (Bonferroni) differences of baseline test medians according to drugs, n = 154.
<p>Summary of significant (Bonferroni) differences of baseline test medians according to drugs, n = 154.</p
Prediction of recovery at inclusion, in adjudicated DILI cases (n = 115).
<p>Prediction of recovery at inclusion, in adjudicated DILI cases (n = 115).</p
Performances of DILI-ActiTest, apoA1 and haptoglobin, for the prediction of recovery.
<p>DILI-ActiTest ‘s AUROC = 0.723 (95%CI 0.610–0.806 P<0.001 vs. 0.5). The AUROCs of APOA1, and HAPTO were 0.663 (0.536–0.76; P = 0.004 vs 0.5; P = 0.14 vs DILI-ActiTest), and 0.619 (0.496–0.718; P = 0.04 vs 0.500; p = 0.05 vs DILI-ActiTest).</p
Flow chart of patients included and analyzed.
<p>Flow chart of patients included and analyzed.</p